During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Saad Z. Usmani, Levine Cancer Institute, Charlotte, US. We asked, Is the bispecific antibody teclistamab safe and effective in patients with relapsed/refractory multiple myeloma (MM)?
In this video, Usmani shares the updated phase I results of teclistamab, a bispecific B-cell maturation antigen x CD3 antibody, in patients with relapsed/refractory MM.